20 Week Bridging Study in Type II DM
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00563225|
Recruitment Status : Completed
First Posted : November 26, 2007
Last Update Posted : November 26, 2007
|Condition or disease||Intervention/treatment||Phase|
|Diabetes Mellitus Type II||Drug: Insulin Glargine||Phase 3|
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||90 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||A Multicenter, Non-Comparative, Open, Phase III Study to Evaluate the Efficacy and Safety of Insulin Glargine on Subjects With Type 2 Diabetes Mellitus|
|Study Start Date :||October 2002|
|Actual Study Completion Date :||April 2004|
- Drug: Insulin Glargine
Insulin glargine at the discretion of the investigator Subcutaneous, once daily injection (at bedtime)Other Name: Lantus
- To evaluate safety & efficacy of Insulin glargine ( injection at bedtime, once a day) on the changes of HbA1c.
- To evaluate the efficacy of Insulin glargine (injection at bedtime, once a day) on the changes of FPG.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00563225
|Study Director:||Choe Seong Choon||Sanofi|